Most strokes and heart attacks are caused by an occlusive intravascular clot. Wallace, MScEng, MBA, TSI co-founder and CEO. “This additional patent in the United States continues to validate TSI’s innovative science while enabling us to further our partnering efforts to bring TSI’s therapeutic solution to patients,” said Alexis C. In our newly patented treatment, which utilizes the sequential combination of tPA and uPA, we have for the very first time an effective and safe treatment for ischemic stroke.” Because of the complementary modes of action of the activators, their combination has a synergistic and more potent effect, so that smaller doses can be used thereby significantly reducing the bleeding risk. Victor Gurewich, MD, Co-founder and Scientific Director of TSI, “the current and longstanding treatment for stroke has used tPA alone, which was a mistake since it is neither sufficiently effective nor safe, and fails to recognize that both activators are needed. TSI’s method is based on an improved understanding of the of the natural biological system, which it mimics to make therapeutic thrombolysis more effective and safer.Īccording to Prof.
The natural system uses both fibrinolytic enzymes, tissue plasminogen activator, tPA, and urokinase plasminogen activator, uPA. Thrombolysis, the biological system responsible for dissolving blood clots, is the fastest, simplest, and most economical way to remove an obstructive clot and reestablish blood flow. The patent was granted for a novel treatment applicable to ischemic stroke, one of the leading causes of morbidity and mortality. US Patents Complement Existing Patent Protection in the US, Europe, Japan, and ChinaĬAMBRIDGE, MA, Janu/ B3C newswire / - Thrombolytic Science, LLC (TSI) has been granted a second patent by the USPTO.
0 kommentar(er)
